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The Influence of Diabetes Mellitus on Glucuronidation and Sulphation of 
Paracetamol in Patients with Febrile Neutropenia 
Abstract 
Background and Objectives Numerous studies have confirmed the influence of diabetes mellitus on the 
pharmacokinetics of drugs. Paracetamol (APAP) is an antipyretic that is commonly used in febrile 
neutropenia (FN) therapy. APAP is chiefly metabolised by glucuronidation and sulphation. This study 
assessed the influence of diabetes on the pharmacokinetics of paracetamol and its metabolites: 
glucuronide (APAP-glu) and sulfate (APAP-sulfate) in FN patients. 
Methods Patients with FN received single intravenous dose 1000 mg of APAP. The FN patients were 
allocated to one of two groups: diabetics (DG, n = 7) or non-diabetics (NDG, n = 11). The plasma 
concentrations of paracetamol and its metabolites were measured with the validated high-performance 
liquid chromatography (HPLC) with ultraviolet (UV) detection. 
Results Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: 
Cmax (maximum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC 0–t (area under the 
concentration–time curve) = 44.23 [17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 
[0.80] vs. 2.11 [0.80] h. In both groups the exposure to APAP was comparable. The study did not reveal 
differences between the two groups in the pharmacokinetics of APAP-glu and APAP-sulfate. The Cmax 
and AUC 0–t ratio between the metabolites and APAP were similar. 
Conclusions No differences in the pharmacokinetics of APAP, APAP-glu and APAP-sulfate in patients with 
FN indicates that diabetes does not influence glucuronidation and sulfatation of paracetamol. 
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Abstract
Background and Objectives Numerous studies have confirmed the influence of diabetes mellitus on the pharmacokinetics 
of drugs. Paracetamol (APAP) is an antipyretic that is commonly used in febrile neutropenia (FN) therapy. APAP is chiefly 
metabolised by glucuronidation and sulphation. This study assessed the influence of diabetes on the pharmacokinetics of 
paracetamol and its metabolites: glucuronide (APAP-glu) and sulfate (APAP-sulfate) in FN patients.
Methods Patients with FN received single intravenous dose 1000 mg of APAP. The FN patients were allocated to one of two 
groups: diabetics (DG, n = 7) or non-diabetics (NDG, n = 11). The plasma concentrations of paracetamol and its metabolites 
were measured with the validated high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection.
Results Pharmacokinetic parameters (mean [SD]) of APAP in the DG and NDG groups were as follows: Cmax (maxi-
mum comcentration) = 21.50 [11.23] vs. 23.42 [9.79] mg/L, AUC 0–t (area under the concentration–time curve) = 44.23 
[17.93] vs. 41.43 [14.57] mg·h/L, t1/2kel (elimination half-life) = 2.28 [0.80] vs. 2.11 [0.80] h. In both groups the exposure to 
APAP was comparable. The study did not reveal differences between the two groups in the pharmacokinetics of APAP-glu 
and APAP-sulfate. The Cmax and AUC 0–t ratio between the metabolites and APAP were similar.
Conclusions No differences in the pharmacokinetics of APAP, APAP-glu and APAP-sulfate in patients with FN indicates 
that diabetes does not influence glucuronidation and sulfatation of paracetamol.
Key points 
Diabetes mellitus does not influence glucuronidation of 
paracetamol.
Diabetes mellitus does not influence sulfatation of par-
acetamol.
1 Introduction
Patients with hematological malignancies usually undergo 
complex therapy, including antipyretic therapy. However, 
cytostatic therapy has the myelotoxic effect. The con-
centration of neutrophils decreases in most patients who 
undergo consecutive courses of chemotherapy. If they 
develop an infection, it usually results in febrile neutrope-
nia (FN). Decreased concentration of neutrophils < 500/µL 
favours rapid development of infections of different aeti-
ologies. When the body temperature reaches > 38.3 °C in 
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one measurement or when it has been ≥ 38 °C for longer 
than one hour, the patient develops FN [1]. Moreover, dia-
betes mellitus may increase the risk of febrile neutropenia 
in cancer patients receiving chemotherapy [2]. Patients with 
hematological cancers usually undergo complex therapy, 
beginning with antipyretic therapy. Paracetamol (APAP) is 
a common antipyretic drug [3]. APAP is eliminated from 
the body in the form of inactive metabolites, mostly glucu-
ronides (40–67%) and sulfates (20–46%). The analgesic is 
to a lesser extent (3–4%) metabolised by cytochrome P450 
(CYP) 2E1—to hepatotoxic N-acetyl-p-benzoquinone imine 
(NAPQI) [4]. The metabolites are eliminated in urine. Only 
about 4–5% is eliminated in an unchanged form through the 
kidneys [4, 5]. Apart from that, diabetes is characterised by 
increased glycation of albumin. In consequence, the binding 
of the drug to the protein may be impaired and its volume 
of distribution may be altered [6, 7]. Little is known about 
the activity of enzymes participating in the second phase 
of metabolism of APAP in diabetic patients. Moreover sig-
nificant differences were observed in pharmacokinetics of 
paracetamol between diabetic and non-diabetic rabbits [8]. 
Therefore, the aim of the study was to assess the influence 
of diabetes on the pharmacokinetics of paracetamol and its 
two metabolites: glucuronide and sulfate in FN patients with 
haematological malignancies.
2  Subject and Methods
2.1  Subjects
The research was approved by the Bioethics Committee, 
University of Medical Sciences, Poznan, Poland (437/16). 
The research was explained to the patients and those who 
signed written informed consent were enrolled in the study. 
It was conducted between July 2016 and February 2017 in 
diabetic and non-diabetic FN patients with hematological 
malignancies. Patients were included in the study if their age 
was > 18 years; they had haematological malignancy, neutro-
penic fever and no history of allergy to paracetamol. Patients 
with neutropenic fever and diagnosed diabetes mellitus were 
enrolled to diabetic group. Diagnosis of diabetes mellitus 
was made by the presence of classic symptoms of hypergly-
cemia and an abnormal blood test (fasting plasma glucose 
concentration ≥ 126 mg/dL). Diabetes were not controlled 
with medication in the diabetic patients. The exclusion cri-
teria were as follows: previous exposure for paracetamol for 
about 16 h, liver insufficiency, pregnancy and lactation, or 
arterial hypertension, acute diarrhoea, gastrointestinal tract 
haemorrhage, ascites, pleural effusion and smokers. Eight-
een patients (13 men, 5 women: 7 diabetics and 11 non-
diabetics) were enrolled in the research.
2.2  Drug administration and blood sampling
A dose of 1000 mg of paracetamol (100 mL of solution; 
Paracetamol B.Braun 10 mg/mL, address of manufac-
ture: 34212 Melsungen, Germany) was administered to 
the patients by intravenous infusion lasting 15 min. Blood 
samples (1 mL) were collected before the drug admin-
istration (0) and 0.083; 0.25; 0.5; 1; 2; 4; 6; 7; 8 h after 
termination of the infusion. The blood samples were trans-
ferred into heparinised tubes and centrifuged at 2880 g 
for 10 min at 4 °C. Next the plasma was transferred to 
propylene tubes and stored at − 80 °C until analysis (max. 
1 month).
2.3  Bioanalytical assay
The reagents used in the research were purchased from the 
following suppliers: paracetamol, theophylline and per-
chloric acid (Sigma Aldrich, Poland), paracetamol glucu-
ronide and paracetamol sulfate (LGC Standards, Poland), 
HPLC (high-performance liquid chromatography) grade 
acetonitrile, methanol and orthophosphoric acid (Merck, 
Poland), sodium sulfate anhydrous (POCH S.A., Poland). 
Water used in the mobile phase was deionised, distilled 
and filtered through a Millipore system (Direct-Q UV3, 
Millipore) before use. Paracetamol B.Braun® 0.01 g/mL 
(batch: 16156451, expiration date: September 2017) was 
purchased from B.Braun®, Melsungen, Germany.
The concentrations of paracetamol, paracetamol glucuro-
nide and paracetamol sulfate were assayed using the HPLC 
method with UV detection [9]. Separation was achieved by 
isocratic elution of the mobile phase, sodium sulfate 0.05 M 
pH 2.2 (adjusted with 85% orthophosphoric acid)—ace-
tonitrile (93:7, v/v), at a flow rate of 1.0 mL/min through 
a Hypersil ODS C18 column (150 mm, 4.6 mm, 5.0 µm 
particle size) (Thermo Electron  Corporation®). The column 
temperature was maintained at 25 °C. The UV detection 
wavelength was set at 254 nm, and the injection volume 
was 50 µL. The total analysis time for each run was 10 min. 
The lower limit of quantification (LLOQ) for paracetamol, 
paracetamol glucuronide and paracetamol sulfate were 0.1, 
0.5  and 0.1 mg/L, respectively. Intra- and inter-day accuracy 
and precision of the LLOQ, low quality control (0.25 , 1.0 , 
0.25 mg/L), medium quality control (20.0, 30.0, 10 mg/L), 
and high quality control (40.0, 50.0, 15.0 mg/L) were well 
within the acceptable limit of 15% coefficient of variation 
(CV%) for paracetamol, paracetamol glucuronide and par-
acetamol sulfate. The calibration was linear within the range 
of 0.1–45 mg/L (r = 0.999) for paracetamol, 0.5–60 mg/L 
(r = 0.999) for paracetamol glucuronide and—0.1–20 mg/L 
(r = 0.998) for paracetamol sulfate.
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2.4  Pharmacokinetic analysis
Pharmacokinetic parameters (Cmax, t1/2kel, Vd/kg—vol-
ume of distribution per kilogram, CL clearance, AUC 0–t, 
 AUMC0–t—area under first moment concentration time 
profile,  MRT0–t mean residual time) were estimated by non-
compartmental methods, using Phoenix™  WinNonlin® v. 
6.3; Certara L.P., USA software (Certara L.P., USA) and 
ThothPro 4.1 (ThothPro Sp. z o.o., Poland).
2.5  Statistical analysis
No study power calculation was performed. The number of 
subjects to be included in the study was based on previous 
similar studies in severely ill patients. Descriptive analysis 
of study results was performed. The results are expressed 
as mean ± SD.
3  Results
In both groups, the mean BMIs (body mass index) of the 
subjects were similar. However, the diabetic patients were 
slightly older (52 [15] vs. 42 [14] years) and their fasting 
serum glucose concentration were significantly higher 
(137.4 vs. 96.1 mg/dL) (Table 1). The creatinine clear-
ance estimated by the Cockroft-Gault formula was below 
the reference values (75–115 mL/min) in 6 patients, but it 
was > 30 mL/min, so it did not indicate renal failure and was 
not a contraindication against APAP. The concentrations of 
hepatic enzymes, i.e. aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) were too high in 4 and 6 
patients, respectively. 17 patients had hypoalbuminaemia, 
which is characteristic of patients treated for haematological 
malignancies.
There was considerable intersubject variability in the 
pharmacokinetic parameters of APAP, APAP-glu and APAP-
sulfate, as evidenced by the CV% [10] (Table 2).
Figures 1 and 2 show mean plasma concentration–time 
profiles for APAP and its metabolites, respectively, in 
both groups during the 8 h period after the administration 
of APAP. Table 2 shows the pharmacokinetics of APAP, 
APAP-glu and APAP-sulfate. We observed no changes in 
the exposure to intravenous APAP, what was reflected by 
similar values of Cmax, AUC 0–t in the groups (Table 2). There 
were also no differences in the following pharmacokinetic 
parameters of APAP: t1/2kel, Vd/kg, Cl,  AUMC0–t,  MRT0–t. 
Similarly, the groups under analysis did not differ in the 
Cmax,  tmax, AUC 0–t, t1/2kel,  AUMC0–t,  MRT0–t of APAP-glu 
and APAP-sulfate. The Cmax and AUC 0–t ratio between the 
metabolites and APAP were similar.
4  Discussion
Diabetes can cause pathophysiological changes in the body 
and affect the pharmacokinetics and pharmacodynamics of 
drugs. These changes include reduction in gastric empty-
ing time, albumin glycation, changes in P-gp expression and 
CYP activity [11–13].
The influence of diabetes on the enzymatic activity at 
the second phase of the drug metabolism has not been 
fully investigated. In order to assess APAP glucuronidation 
and sulphation the pharmacokinetic parameters of APAP 
and its glucuronide and sulfate were compared in patients 
with FN between the groups of diabetic and non-diabetics. 
Table 1  The characteristics of 
patients with febrile neutropenia
 BMI body mass index, Ccr creatinine concentration, CLCR creatinine clearance estimated by the Cockroft-
Gault formula, AST aspartate aminotransferase, ALT alanine aminotransferase
a Values are expressed as the mean ± standard deviation
Parameter Valuea
Diabetic group Non-diabetic group
Males/females [n] 4/3 9/2
Age [years] 52 ± 15 (33–73) 42 ± 14 (19–57)
Weight [kg] 80 ± 24 (49–120) 84 ± 17 (60–107)
BMI [kg/m2] 27.1 ± 7.3 (18.2–36.2) 26.2 ± 5.4 (19.3–36.1)
Fasting glucose [mg/dL] 137.4 ± 45.9 (98.8–235.1) 96.1 ± 12.8 (83.3–119.0)
Ccr [mg/dL] 1.11 ± 0.45 0.99 ± 0.72
CLCR [mL/min] 109.4 ± 77.8 (24.7–262.7) 104.8 ± 66.3 (49.9–297.4)
Total bilirubin [µmol/L] 11.0 ± 6.4 (3.7–19.4) 11.6 ± 6.4 (4.9–21.7)
Albumin [g/L] 27.5 ± 5.6 (20.3–32.6) 26.8 ± 6.0 (19.6–39.6)
AST [U/L] 28 ± 15 (12–52) 18 ± 10 (8–41)
ALT [U/L] 85 ± 71 (15–234) 46 ± 37 (11–118)
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Pharmacokinetic parameters of APAP and its metabolites 
were comparable between diabetic and non-diabetic patients 
with FN. It might indicate that the diabetes does not influ-
ence the pharmacokinetics of paracetamol and its metabo-
lites in patients with FN. Apart from that, the similar values 
of APAP-glu/APAP and APAP-sulfate/APAP ratios between 
the groups show that the disease seems not influence glu-
curonidation and sulphation of the analgesic (see Table 2).
Studies have shown that FN patients may exhibit hypoal-
buminaemia, and in consequence increased volume of dis-
tribution and clearance of the drugs [8, 14]. Therefore, the 
pharmacokinetic parameters of APAP observed in the FN 
patients were compared with the data published in the lit-
erature [15, 16]. The pharmacokinetic parameters of APAP 
observed in the FN patients (AUC 0–t, FN = 42.5 mg·h/L; 
Cmax, FN = 22.7 mg/L; t1/2, FN = 2.2 h; Vd, FN = 0.83 L/kg) were 
comparable with the values observed in healthy volunteers 
(AUC 0–t = 42.5 mg·h/L; Cmax = 21.6 mg/L; t1/2 = 2.2 h; Vd = 1 
L/kg) [12, 16]. Only the drug clearance was slightly greater 
(27.4 vs. 20.7 L/h).
The research was limited by the small number of par-
ticipants. Therefore, it should be continued on larger 
groups of patients. It is acceptable to administer APAP 
to patients with liver failure if a dose of ≤ 3000 mg is not 
Table 2  Pharmacokinetic 
parameters for paracetamol 
(APAP) and its metabolites—
glucuronide (APAP-glu) and 
sulfate (APAP-sulfate) in 
patients with neutropenic fever
AUC 0–t area under the plasma concentration–time curve from zero to the time of last measurable concentra-
tion, Cmax maximum observed plasma concentration, tmax time to first occurrence of Cmax, t1/2kel half-life in 
elimination phase, Cl clearance (Cl), Vd/kg volume of distribution per kilogram, AUMC0–t area under the 
first moment curve from zero to the time of last measurable concentration, MRT0–t mean residence time, M 
Arithmetic mean, SD standard deviation, CV coefficient of variation
a Ratio of paracetamol glucuronide/paracetamol
b Ratio of paracetamol sulfate/paracetamol
c Values are expressed as the mean ± standard deviation (%CV)







 Cmax [mg/L] 21.50 ± 11.23 (52.2) 23.42 ± 9.79 (41.8)
 t1/2kel [h] 2.28 ± 0.80 (35.1) 2.11 ± 0.80 (38.0)
 Vd/kg [L/kg] 0.87 ± 0.36 (41.2) 0.80 ± 0.36 (45.7)
 CL [h] 24.56 ± 11.08 (45.1) 29.24 ± 21.28 (72.8)
 AUC 0–t [mg·h/L] 44.23 ± 17.93 (40.5) 41.43 ± 14.57 (35.2)
 AUMC0–t [mg·h2/L] 104.23 ± 51.55 (49.5) 93.12 ± 37.60 (40.1)
 MRT0–t [h] 2.23 ± 0.38 (17.0) 2.15 ± 0.41 (19.2)
APAP-glu
 Cmax [mg/L] 24.03 ± 10.49 (43.7) 20.05 ± 14.48 (72.2)
 tmax [h] 2.00 ± 1.41 (70.7) 1.03 ± 0.71 (69.4)
 t1/2kel [h] 13.21 ± 25.87 (195.9) 4.54 ± 3.42 (69,4)
 AUC 0–t [mg·h/L] 117.52 ± 41.43 (35.3) 110.06 ± 105.71 (96.1)
 AUMC0–t [mg·h2/L] 387.93 ± 144.51 (37.3) 384.78 ± 408.27 (101.6)
 MRT0–t [h] 3.20 ± 0.48 (14.9) 3.17 ± 0.49 (72.2)
APAP-sulfate
 Cmax [mg/L] 6.29 ± 5.63 (89.5) 6.99 ± 3.02 (43.2)
 tmax [h] 1.40 ± 0.55 (39.1) 1.33 ± 0.75 (56.5)
  t1/2kel [h] 2.68 ± 0.56 (21.0) 2.07 ± 0.48 (23.3)
 AUC 0–t [mg·h/L] 34.23 ± 30.65 (89.5) 35.73 ± 21.04 (58.9)
 AUMC0–t [mg·h2/L] 119.19 ± 110.67 (92.9) 115.70 ± 72.57 (62.7)
 MRT0–t [h] 3.08 ± 0.71 (23.2) 3.03 ± 0.23 (8.1)
APAP-glu/APAPa
 AUC 0–t 2.93 ± 1.34 (42.4) 1.87 ± 0.69 (105.4)
 Cmax 1.19 ± 0.33 (25.87) 0.76 ± 0.31 (110.8)
APAP-sulfate/APAPb
 AUC 0–t 0.77 ± 0.55 (89.6) 0.98 ± 0.37 (62.1)
 Cmax 0.32 ± 0.27 (106.2) 0.35 ± 0.15 (70.0)
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exceeded [11]. Another limitation is that we did not meas-
ure NAPQI, which is a hepatotoxic APAP metabolite.
5  Conclusion
Based on the results of this study, it seems that diabetes 
does not influence glucuronidation and sulfatation of par-
acetamol in patients with FN. Therefore, paracetamol may 
be given to these patients without any dose adjustment.
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Fig. 1  Paracetamol (APAP) 
plasma concentration vs. 
time profiles following single 
intravenous administration of 
paracetamol to patients with 
febrile neutropenia (diabetic 
vs. non-diabetic group). Plots 
























Fig. 2  Paracetamol glucuronide 
(APAP-glu) and paraceta-
mol sulphate (APAP-sulfate) 
plasma concentrations vs. 
time profiles following single 
intravenous (i.v.) administration 
of paracetamol to patients with 
febrile neutropenia (diabetic 
vs. non-diabetic group). Plots 
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